Kineta announced the presentation of new preclinical data on the company’s anti-CD27 agonist monoclonal antibodies in development for the treatment of advanced solid tumors at the American Association for Cancer Research, AACR, Special Conference on Tumor Immunology and Immunotherapy. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, unveiled new preclinical data in the company’s poster titled “CD27 is a new promising T cell co-stimulatory target for cancer immunotherapy”. The company’s leading mAb candidates showed high affinity binding to both human and cynomolgus monkey CD27, as well as high specificity against CD27, with no cross-reactivity detected against other members of the tumor necrosis factor receptor super family. Additionally, none of the selected mAbs block the binding of CD27 natural ligand, CD70.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KA:
- Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
- Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Kineta announces KVA12123 data from Phase 1/2 VISTA-101 trial
- Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
- Kineta Announces Participation at October Investor Conferences